Opening Road to COVID Vaccines: Past, Present, and Future
Road to COVID Vaccines: Past, Present, and Future
- Length
- 59 min
- Level
- Graduate
- Recorded
- University of Washington2022
Chapter 1 of 9: Before the lecture
Corey traces COVID-19 vaccines from prefusion spike stabilization to harmonized trials and Delta-era boosters.
COVID-19 vaccines came quickly because of twenty years of investment in structural biology, mRNA modification and clinical trial networks, Lawrence Corey argues in this Laboratory Medicine Grand Rounds session. He starts with the U.S. government's coordinated strategy, then shows how proline substitutions lock the spike protein in its prefusion state and yield more potent neutralizing antibodies. Harmonized trials shared common endpoints, standardized laboratories and a single data and safety monitoring board across several vaccine platforms. Corey describes recruitment of diverse volunteers through the Coronavirus Prevention Network and a national registry, and the defence of trial integrity during the 2020 election. He closes by weighing evidence on the Delta variant, waning antibody titers and boosters.
COVID-19 vaccines came quickly because of twenty years of investment in structural biology, mRNA modification and clinical trial networks, Lawrence Corey argues in this Laboratory Medicine Grand Rounds session. He starts with the U.S. government's coordinated strategy, then shows how proline substitutions lock the spike protein in its prefusion state and yield more potent neutralizing antibodies. Harmonized trials shared common endpoints, standardized laboratories and a single data and safety monitoring board across several vaccine platforms. Corey describes recruitment of diverse volunteers through the Coronavirus Prevention Network and a national registry, and the defence of trial integrity during the 2020 election. He closes by weighing evidence on the Delta variant, waning antibody titers and boosters.
A Proof of Concept for Structure-Based Vaccine Design Targeting RSV in Humans
Immunogenicity and Structures of a Rationally Designed Prefusion MERS-CoV Spike Antigen
A Strategic Approach to COVID-19 Vaccine R&D
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys
New England Journal trial results

This lecture
Talk 9 of 14 of Laboratory Medicine Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
Bar-On, et al. Protection of BNT162b2 Vaccine Booster Against Covid-19 in Israel
David Leonhardt, NYT 9/27/2021
Preprint on correlate of protection for the Moderna trial